Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2015, Article ID 431819, 5 pages
http://dx.doi.org/10.1155/2015/431819
Case Report

Antiangiogenic Therapies and Extracranial Metastasis in Glioblastoma: A Case Report and Review of the Literature

1Department of Radiation Oncology & Molecular Radiation Sciences, Johns Hopkins University, 401 North Broadway, Suite 1440, Baltimore, MD 21231-5678, USA
2Department of Radiation Oncology, Case Western Reserve University, University Hospitals Seidman Cancer Center, Cleveland, OH 44106, USA
3Department of Neurosurgery, Johns Hopkins University, 600 N. Wolfe Street, Phipps Room 123, Baltimore, MD 21287, USA
4Department of Neurology/Neuro-Oncology, Johns Hopkins University, 601 N. Caroline Street, Baltimore, MD 21287, USA

Received 26 January 2015; Revised 16 June 2015; Accepted 17 June 2015

Academic Editor: Se-Hoon Lee

Copyright © 2015 Mohamed H. Khattab et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Stupp, W. P. Mason, M. J. van den Bent et al., “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” The New England Journal of Medicine, vol. 352, no. 10, pp. 987–996, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Lun, E. Lok, S. Gautam, E. Wu, and E. T. Wong, “The natural history of extracranial metastasis from glioblastoma multiforme,” Journal of Neuro-Oncology, vol. 105, no. 2, pp. 261–273, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. G. Kalokhe, S. A. Grimm, J. P. Chandler, I. Helenowski, A. Rademaker, and J. J. Raizer, “Metastatic glioblastoma: case presentations and a review of the literature,” Journal of Neuro-Oncology, vol. 107, no. 1, pp. 21–27, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Muller, J. Holtschmidt, M. Auer et al., “Hematogenous dissemination of glioblastoma multiforme,” Science Translational Medicine, vol. 6, no. 247, p. 247ra101, 2014. View at Publisher · View at Google Scholar
  5. E. di Tomaso, M. Snuderl, W. S. Kamoun et al., “Glioblastoma recurrence after cediranib therapy in patients: lack of ‘rebound“ revascularization as mode of escape,” Cancer Research, vol. 71, no. 1, pp. 19–28, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. J. F. de Groot, G. Fuller, A. J. Kumar et al., “Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice,” Neuro-Oncology, vol. 12, no. 3, pp. 233–242, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. M. R. Mancuso, R. Davis, S. M. Norberg et al., “Rapid vascular regrowth in tumors after reversal of VEGF inhibition,” Journal of Clinical Investigation, vol. 116, no. 10, pp. 2610–2621, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. F. M. Iwamoto, L. E. Abrey, K. Beal et al., “Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma,” Neurology, vol. 73, no. 15, pp. 1200–1206, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Ricci-Vitiani, R. Pallini, M. Biffoni et al., “Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells,” Nature, vol. 468, no. 7325, pp. 824–830, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. E. M. Thompson, E. P. Frenkel, and E. A. Neuwelt, “The paradoxical effect of bevacizumab in the therapy of malignant gliomas,” Neurology, vol. 76, no. 1, pp. 87–93, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Shweiki, A. Itin, D. Soffer, and E. Keshet, “Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis,” Nature, vol. 359, no. 6398, pp. 843–845, 1992. View at Publisher · View at Google Scholar · View at Scopus
  12. B. Millauer, L. K. Shawver, K. H. Plate, W. Risau, and A. Ullrich, “Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant,” Nature, vol. 367, no. 6463, pp. 576–579, 1994. View at Publisher · View at Google Scholar · View at Scopus
  13. T. T. Batchelor, P. Mulholland, B. Neyns et al., “Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma,” Journal of Clinical Oncology, vol. 31, no. 26, pp. 3212–3218, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. S. L. Gerson, “MGMT: its role in cancer aetiology and cancer therapeutics,” Nature Reviews Cancer, vol. 4, no. 4, pp. 296–307, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. M. E. Hegi, A.-C. Diserens, T. Gorlia et al., “MGMT gene silencing and benefit from temozolomide in glioblastoma,” The New England Journal of Medicine, vol. 352, no. 10, pp. 997–1003, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Li, Z. Zhang, J. Zhang et al., “Occipital anaplastic oligodendroglioma with multiple organ metastases after a short clinical course: a case report and literature review,” Diagnostic Pathology, vol. 9, no. 1, article 17, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Esteller, S. R. Hamilton, P. C. Burger, S. B. Baylin, and J. G. Herman, “Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia,” Cancer Research, vol. 59, pp. 793–797, 1999. View at Google Scholar
  18. V. Voelter, A.-C. Diserens, A. Moulin et al., “Infrequent promoter methylation of the MGMT gene in liver metastases from uveal melanoma,” International Journal of Cancer, vol. 123, no. 5, pp. 1215–1218, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Brabender, H. Usadel, R. Metzger et al., “Quantitative O6-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome,” Clinical Cancer Research, vol. 9, no. 1, pp. 223–227, 2003. View at Google Scholar · View at Scopus
  20. M. R. J. Kohonen-Corish, W. A. Cooper, J. Saab, J. F. Thompson, R. J. A. Trent, and M. J. Millward, “Promoter hypermethylation of the O6-methylguanine DNA methyltransferase gene and microsatellite instability in metastatic melanoma,” Journal of Investigative Dermatology, vol. 126, no. 1, pp. 167–171, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. N. Shinojima, K. Tada, S. Shiraishi et al., “Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme,” Cancer Research, vol. 63, no. 20, pp. 6962–6970, 2003. View at Google Scholar · View at Scopus
  22. U. Tabori, S. Rienstein, Y. Dromi et al., “Epidermal growth factor receptor gene amplification and expression in disseminated pediatric low-grade gliomas,” Journal of Neurosurgery, vol. 103, no. 4, pp. 357–361, 2005. View at Google Scholar · View at Scopus